title: Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1.
abstract: OBJECTIVE
  To determine whether enzyme therapy with imiglucerase/alglucerase demonstrates dose-response relationships with doses and disease parameters used in routine clinical practice for Gaucher disease type 1 patients.
  
  
  METHODS
  Analyses included all patients with Gaucher disease type 1 on enzyme therapy and with intact spleens in the large observational database of the International Collaborative Gaucher Group Gaucher Registry. Propensity scoring was used to match patients between enzyme therapy dose groups categorized as Group A (5 U to <29 U/kg/2 weeks), Group B (29 U to <48 U/kg/2 weeks), Group C (48 U to <75 U/kg/2 weeks). Hemoglobin concentration, platelet count, and hepatic and splenic volumes were assessed after initiation of enzyme therapy using nonlinear mixed effects models. The maximal effect (Emax) and half-time to Emax (T50) of enzyme therapy for each parameter were compared across dosing groups.
  
  
  RESULTS
  Propensity score matching resulted in three comparable groups of 122 patients each (enzyme therapy in Groups A, B, and C). Dose-response relationships were found with regard to Emax and T50 over 96 months for each disease parameter.
  
  
  CONCLUSIONS
  Enzyme therapy with imiglucerase/alglucerase displays a dose-dependent improvement in hematological and visceral parameters in Gaucher disease type 1 patients. Group C displayed greater treatment effects than Groups A or B. Propensity score matching and nonlinear mixed effects model analyses provide a prototype for assessment of treatment outcomes based on observational data from international rare disease registries.
authors.affiliation: Cincinnati Children's Hospital Medical Center, Division of Human Genetics, Cincinnati, Ohio 45229-3039, USA. greg.grabowski@cchmc.org
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Grabowski
authors.forename: Katherine
authors.initials: K
authors.lastname: Kacena
authors.forename: J Alexander
authors.initials: JA
authors.lastname: Cole
authors.forename: Carla E M
authors.initials: CE
authors.lastname: Hollak
authors.forename: Lin
authors.initials: L
authors.lastname: Zhang
authors.forename: John
authors.initials: J
authors.lastname: Yee
authors.forename: Pramod K
authors.initials: PK
authors.lastname: Mistry
authors.forename: Ari
authors.initials: A
authors.lastname: Zimran
authors.forename: Joel
authors.initials: J
authors.lastname: Charrow
authors.forename: Stephan
authors.initials: S
authors.lastname: vom Dahl
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D005260:Female; D005776:Gaucher Disease / Q000188:drug therapy*; D005962:Glucosylceramidase / Q000008:administration & dosage*; D006801:Humans; D007223:Infant; D008297:Male; D012042:Registries; D016896:Treatment Outcome
chemical_list: C070292:alglucerase; D005962:Glucosylceramidase; C090568:imiglucerase